--- title: "JP Morgan maintains Halozyme Therapeutics at Neutral, raises price target to $81 from $79" type: "News" locale: "en" url: "https://longbridge.com/en/news/306311142.md" description: "JP Morgan maintained its Neutral rating on Halozyme Therapeutics, raising the price target to $81 from $79. This adjustment implies a 12.9% downside from the November 19 close of $93.04. Recent analyst actions over the past 30 days show price targets ranging from $109 to $149, with firms like HC Wainwright & Co. reiterating Buy ratings while others have downgraded or maintained their positions." datetime: "2026-11-20T17:35:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/306311142.md) - [en](https://longbridge.com/en/news/306311142.md) - [zh-HK](https://longbridge.com/zh-HK/news/306311142.md) generator: "portal-rs" --- # JP Morgan maintains Halozyme Therapeutics at Neutral, raises price target to $81 from $79 JP Morgan maintained Halozyme Therapeutics at Neutral and raised its price target to $81 from $79, a 2.5% increase. The price target implies a downside of 12.9% from the Nov 19 close of $93.04. **Recent analyst actions on Halozyme Therapeutics** | Date | Firm | Action | Rating | Price target | | ------ | ------------------- | ---------- | ----------------- | ------------ | | Nov 20 | HC Wainwright & Co. | Reiterates | Buy | $130 | | Nov 11 | Morgan Stanley | Downgrades | Equal-Weight | $109 | | Nov 6 | Leerink Partners | Downgrades | Market Perform | $117 | | Nov 6 | Citizens | Maintains | Market Outperform | $149 | | Nov 6 | Evercore ISI Group | Maintains | Outperform | $125 | Across the five most recent analyst notes published on Halozyme Therapeutics over the past 30 days, price targets range from $109 to $149. Explore more price target data and ratings for Halozyme Therapeutics on the , and track all previous and future analyst recommendations in the dedicated News Flow. **Disclaimer** Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice. ### Related Stocks - [HALO.US](https://longbridge.com/en/quote/HALO.US.md) ## Related News & Research - [Halozyme Therapeutics Director Matthew L. Posard Reports Sale of 5,000 Common Shares for $482,146.60](https://longbridge.com/en/news/306031595.md) - [Halozyme Therapeutics President and CEO Helen Torley Reports Sale of $6 Million in Common Shares](https://longbridge.com/en/news/305745734.md) - [Morgan Stanley downgrades Halozyme Therapeutics to Equal-Weight from Overweight, raises price target to $109](https://longbridge.com/en/news/305201443.md) - [Why Is Halozyme Therapeutics (HALO) Drawing Fresh Attention Today?](https://longbridge.com/en/news/305400860.md) - [Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure](https://longbridge.com/en/news/306160621.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**